When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada

Area of Science:

• Health Policy
• Pharmacoeconomics
• Drug Development

Background:

• The existing framework for rare and orphan diseases, exemplified by the US Orphan Drug Act, utilizes broad criteria and market incentives.
• This model has been adopted by other countries, shaping drug development for rare conditions.
• Concerns exist regarding the equitable development of therapies for all rare diseases.

Purpose of the Study:

• To argue for a novel approach to rare and orphan diseases.
• To critically evaluate the current US-centric orphan drug model.
• To advise against Canada adopting the US model for its developing orphan drug framework.

Main Methods:

• Critical analysis of the current orphan drug framework.
• Examination of industry trends and personalized medicine advancements.
• Review of empirical evidence on orphan drug market focus.

Main Results:

• The biopharmaceutical industry shows increasing interest in orphan diseases.
• Personalized medicine is leading to the reclassification of common diseases as rare.
• Empirical data indicates that orphan drugs often target a narrow, profitable segment of rare diseases.

Conclusions:

• The current US orphan drug model is inadequate for addressing the full spectrum of rare diseases.
• Canada should not replicate the US model due to its limitations and potential for inequitable drug development.
• A new, more comprehensive framework is essential for rare and orphan diseases.